Welcome to the 2nd Donor Selection & Cell Source Summit
The ONLY Meeting Keeping Donors at the Heart of the Conversation
It is known that suboptimal donor selection in allogeneic therapies can compromise treatment efficacy and patient safety. Raising the question: are our current donor selection criteria robust enough to meet the growing demands and challenges in this critical field?
As the clinical landscape for allogeneic therapies continues to evolve, the challenging reality of achieving true scalability is setting in for the field, with all eyes turning to the backbones of these universal therapies to ensure a high-quality and scalable product can be achieved through a well-thought-out donor plan.
The 2nd Donor Selection & Cell Source Summit provides an unparalleled opportunity to delve into the latest global regulatory requirements and variations in donor testing, cutting-edge genome sequencing data driving donor selection, establishing new partnerships to streamline logistical coordination with donation sites and ensuring exclusive access to chosen donor pools.
We Collaborated with Bristol Myers Squibb, ImmuneBridge, Deverra Therapeutics & more!
Together, We Can Revolutionize the Future of Allogeneic Therapies & Significantly Enhance Patient Outcomes
Join us this year to participate in this industry-defining forum specifically designed to inspire and facilitate transparent and interactive discussions on how to transform off-the-shelf cell therapies right from the start.
By refining our donor selection processes today, we can revolutionize the future of allogeneic therapies and significantly enhance patient outcomes.
2024 Expert Speakers
Previously Attending Companies Include
Our Partners
